Search results
Results From The WOW.Com Content Network
Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. ... Before you buy stock in ...
Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 9% from a peak the stock set in ...
Here's why they think Eli Lilly (NYSE: LLY), Intuitive Surgical (NASDAQ: ISRG), and Vertex Pharmaceuticals (NASDAQ: VRTX) are unstoppable stocks to buy in 2025. ... the stock has jumped close to ...
At recent prices, you can buy Vertex stock for about 35.2 times trailing free cash flow. This is a high multiple, but the business is growing fast enough to justify the valuation.
Vertex Pharmaceuticals (NASDAQ: VRTX) might be one of those special cases. Should you buy Vertex stock hand over fist before Jan. 30? Vertex built its business treating the underlying genetic ...
Vertex Pharmaceuticals (NASDAQ: VRTX) is trading near a record high after climbing about 20% so far this year, and delivering a triple-digit gain over three years. So, you may be a bit hesitant ...
Notably, Vertex Pharmaceuticals (NASDAQ: VRTX), which focuses on developing treatments for rare diseases, has significantly outpaced both its biotechnology peers and the S&P 500 since early 2022.
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.